Sign in
Not yet taking people in United StatesPhase 1/2

Long-term safety follow-up of EG110A gene therapy for overactive bladder after spinal cord injury

Follows people with overactive bladder and spinal cord injury who received EG110A earlier.

Key facts

Who runs it
Cyllene Therapeutics
Where
Ann Arbor, Downey, Houston, and Philadelphia, United StatesSee the 4 sites
Trial code
Registry title
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
16 people, planned
Started
Apr 2026
Expected to end
Apr 2031
Type of study
Interventional
Treatments tested
  • Urodynamics
  • EG110A
  • Patient-reported Outcome
Record updated
12 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who got at least one dose of EG110A in Study EG110A-001-01. It follows them for five years to check safety and side effects.

Age
18 Years to 75 Years
Sex
All sexes can join
Disease stage
People with overactive bladder linked to spinal cord injury who took part in the earlier EG110A study, and either finished it or left it early.
Earlier treatment
Must have received at least one dose or injection of EG110A in Study EG110A-001-01.

Main reasons for not taking part

  • Plans to join another gene therapy study that is still being tested
  • An uncontrolled illness or other disorder that would make it hard to follow the study rules, as judged by the study doctor
  • Current substance abuse that would make it hard to follow the study rules

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • All participants who received at least one dose/injection of EG110A in Study EG110A-001-01 and have prematurely discontinued or completed that study

Who cannot take part

  • Participant plans to participate in another investigational gene therapy study
  • Participant has an uncontrolled intercurrent illness, any disorder, or current substance abuse that would limit compliance with study requirements in the opinion of the investigator

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • University of Michigan Rogel Cancer CenterAnn Arbor, United StatesContact: John Stoffel, MDNot yet recruiting
  • Rancho Los Amigos National Rehabilitation CenterDowney, United StatesContact: Evgeniy Kreydin, MDNot yet recruiting
  • UTHealth Houston / TIRR Memorial HermannHouston, United StatesContact: Argyrios Stampas, MDNot yet recruiting
  • Sidney Kimmel Medical CollegePhiladelphia, United StatesContact: Patrick Shenot, MDNot yet recruiting

About the trial

What the trial wants to find out

The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.

The group in the trial

  • Patients who received EG110A in a clinical study, regardless of doseTreatment being tested

    Treatment: Urodynamics, EG110A, and Patient-reported Outcome

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F
Plain-language title
Long-term safety follow-up of EG110A gene therapy for overactive bladder after spinal cord injuryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07227285, who can take part
Record updated
12 November 2025